A 0001

Drug Profile

A 0001

Alternative Names: A-0001; alpha-tocopherol quinone; EPIA-0001

Latest Information Update: 26 Mar 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Edison Pharmaceuticals
  • Developer Endo Pharmaceuticals
  • Class Coenzymes; Eye disorder therapies; Neuropsychotherapeutics
  • Mechanism of Action Mitochondrial membrane transport protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Friedreich's ataxia

Highest Development Phases

  • Discontinued Friedreich's ataxia; MELAS syndrome

Most Recent Events

  • 29 Feb 2012 Discontinued - Phase-II for Friedreich's ataxia in USA (PO)
  • 29 Feb 2012 Discontinued - Phase-II for MELAS syndrome in England (PO)
  • 11 Jun 2011 Pharmacodynamics, adverse event and preliminary efficacy data from a phase IIa trial in Friedreich's ataxia released by Edison Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top